Urea is something your kidneys deal with quietly every day. Your body breaks down protein, produces ammonia as a byproduct, converts it into urea, and flushes it out through urine. Most people never think about it twice. But researchers at the University of Manchester have found urea doing something it absolutely should not be doing: accumulating deep inside the brain, in concentrations high enough to suggest it may be killing nerve cells in two of the most devastating diseases science has yet to cure.
The diseases in question are frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). They differ in their symptoms and the parts of the brain they attack, yet scientists have long suspected they share some underlying biological thread. The new research, published in July 2026 in the journal Molecular Omics, offers the strongest evidence yet that the thread may be a failure of waste clearance, specifically brain urea buildup that the brain can no longer remove fast enough.
What makes this finding particularly striking is that it didn’t come from animal models or lab-grown tissue. Researchers measured urea in different regions of the brain using highly sensitive laboratory techniques, comparing brain tissue from people who had FTD or ALS with tissue from people without neurological disease, all of whom had donated their bodies to scientific research after death. The differences they found were not subtle.
What Urea Is and Why It Shouldn’t Be in Your Brain
Researchers found unusually high levels of urea, a waste chemical normally flushed out in urine, in the brains of people with frontotemporal dementia and amyotrophic lateral sclerosis. To understand why that’s alarming, it helps to understand the urea cycle itself. The urea cycle involves a series of biochemical steps in which nitrogen, a waste product of protein metabolism, is converted into urea so that the body can excrete it safely. Under normal conditions, healthy kidneys handle this efficiently and the compound never builds up anywhere it isn’t supposed to.
The brain has its own waste removal infrastructure. Compelling evidence solidifies the glymphatic system’s dependence on deep, non-rapid eye movement (NREM) sleep for the efficient clearance of neurotoxic metabolic byproducts. This system, a network of fluid-filled channels that runs alongside blood vessels, uses cerebrospinal fluid (the clear liquid that cushions the brain and spinal cord) to flush waste out of brain tissue during sleep. Glymphatic flow is primarily active during sleep and driven by cerebrovascular arterial pulsations; a reduction in glymphatic flow results in accumulation of protein in the brain that leads to neurodegeneration.
When this system underperforms, waste accumulates. The Manchester team’s findings suggest that urea may be among the most consequential of those accumulated substances. A 2025 study published in npj Parkinson’s Disease found shared urea cycle abnormalities across diverse neurodegenerative diseases, suggesting a convergent pathway of urea metabolism disruption that cuts across conditions long thought to be entirely separate.
Two Diseases, One Shared Mechanism
Previous work by the same research group had already shown this toxic waste buildup in five other dementias, including Alzheimer’s and Parkinson’s-related dementia, but this is the first time it has been confirmed in FTD and ALS. Extending the pattern to two more diseases is significant because FTD and ALS are not mild or rare conditions.
Frontotemporal dementia typically affects people younger than 65 at a rate of around 15.1 cases per 100,000 each year, while ALS is rarer, with about 2.1 new cases per 100,000, according to Medical Xpress’s coverage of the study. Both are incurable and often fatal. The research raises fresh questions about how the brain clears harmful substances.
FTD is distinct from Alzheimer’s in important ways. Rather than attacking memory first, in people with FTD, this toxic waste was not just in the most damaged areas but spread in both damaged areas and relatively spared areas, while in ALS it was mainly concentrated in regions controlling movement. That spatial pattern matters for what the researchers concluded next. Urea accumulation in relatively undamaged regions of FTD brains suggests the problem precedes cell death, not the other way around. The waste may be building up before the worst of the damage occurs.
These findings suggest waste removal problems might occur early, before extensive brain damage. If that interpretation holds up in follow-on research, it would shift how scientists think about disease progression in both conditions and potentially open early intervention windows that currently don’t exist.
The ALS Side of the Equation
ALS is already one of the cruelest diseases in medicine. Using highly sensitive lab techniques, the team measured urea levels in different parts of the brain; in ALS it was mainly concentrated in regions controlling movement. That concentration aligns precisely with ALS’s clinical profile, since the disease attacks motor neurons (the nerve cells that carry signals from the brain to the muscles) and results in progressive loss of voluntary movement. According to Medscape’s clinical overview, the median survival for ALS is just three years from the clinical onset of weakness.
The disease-to-disease overlap between ALS and FTD is also well-documented and adds biological weight to the urea hypothesis. Previous work by the same group had already shown this toxic waste buildup in five other dementias, and this is the first time it has been confirmed in FTD and ALS. More specifically, University of Manchester researchers noted that up to 15% of ALS patients also develop FTD and around half show some level of cognitive problems. Two diseases with distinct clinical presentations, overlapping neurobiology, and now overlapping biochemistry – signposting researchers toward a common mechanism.
Why Urea May Be Toxic to Brain Cells
The working theory is that accumulated urea poisons nerve cells over time, though the exact mechanism is still being studied. What researchers know from kidney disease offers a useful reference point: when the kidneys fail and urea builds up in the blood, a condition called uremic encephalopathy (brain dysfunction caused by kidney failure’s toxins) can occur, causing confusion, seizures, and even coma. Urea increases in neurodegenerative diseases are substantive, and approximate in magnitude to levels present in uraemic encephalopathy, according to a 2021 study in Frontiers in Molecular Neuroscience, suggesting the concentrations seen in these brains are not trivially small.
The urea may also disrupt protein folding or interfere with cellular energy metabolism, though confirming those pathways will require further work. The Manchester group’s data show the compound present in disease-specific regions, at disease-specific concentrations, which researchers consider strong circumstantial evidence of a pathogenic role.
Dr. Sasha Philbert, an Alzheimer’s Society Postdoctoral Fellow and the study’s lead author from the University of Manchester, explained the broader implications directly: “This is exciting because it suggests we might be looking at a common problem underlying several different brain diseases, rather than separate conditions with completely different causes. If we can work out why this waste is building up and how to clear it, we may be able to slow or even stop these diseases, opening the door to new treatments for conditions that currently have very few options.”
The Glymphatic System’s Role in Clearance Failure
The fact that brain urea buildup appears across multiple neurodegenerative diseases suggests the issue may be less about how much urea is produced and more about how effectively the brain removes it. A 2026 study published in Nature Communications found that sleep-active physiological processes, particularly reduced brain parenchymal resistance, enhance overnight glymphatic clearance of biomarkers into plasma. When sleep quality deteriorates, so does the brain’s ability to flush these waste products.
Common and highly prevalent clinical conditions, including obstructive sleep apnea, chronic insomnia, and circadian rhythm disorders, have been shown to fundamentally disrupt this vital clearance process. Whether disrupted glymphatic function is a cause or consequence of urea accumulation in diseases like FTD and ALS remains an open question. But the pattern is consistent enough across diseases that researchers are treating clearance dysfunction as a meaningful target in its own right.
Understanding what drives urea retention in the brain, whether it’s a failure of the glymphatic system, a dysfunction in the urea cycle enzymes themselves, or some combination of both, is now a priority for this research group. Eating a diet that supports brain health over the long term may also matter. Early research suggests that supporting cognitive function through diet could play a role in reducing overall neurodegeneration risk, though no dietary intervention has been tested specifically for urea clearance.
Read More: Signs You Should Look Out For That May Indicate ‘Pre-Dementia’
What This Means for You
This research is still in an early phase. The study used post-mortem brain tissue, which establishes association rather than definitive cause. Future work will need to determine whether urea accumulation is a driver of cell death or a downstream marker of a disease process that’s already underway. Animal studies, longitudinal imaging research, and eventually clinical trials targeting urea clearance will all be necessary before any treatment emerges.
If scientists can understand why urea accumulates in the brain and how to remove it more effectively, they may be able to slow or halt the progression of FTD, ALS and other dementias. By understanding why urea accumulates and how to enhance its removal from the brain, scientists could develop therapies targeting a mechanism shared across multiple currently incurable diseases.
The Sleep Connection You Can Act On Now
For people with a family history of FTD or ALS, the most practical takeaway right now is to keep an eye on the factors known to support glymphatic function. Consistent, quality sleep is the most evidence-backed lever. The glymphatic system depends on deep, non-rapid eye movement sleep for the efficient clearance of neurotoxic metabolic byproducts, which means that chronic sleep disruption isn’t just a fatigue issue. It may be a brain waste clearance issue with consequences that extend over decades. Treating conditions like sleep apnea, maintaining regular sleep schedules, and limiting alcohol, which fragments sleep architecture, all support the system that appears central to this newly identified pathway.
The broader picture emerging from this line of research is one of a brain whose waste systems slowly fail, allowing compounds like urea to build up in regions that govern who we are and how we move. Whether targeting those systems produces effective treatments remains to be seen, but the identification of brain urea buildup as a potentially shared mechanism across seven or more neurodegenerative diseases is the kind of finding that redirects research attention and funding toward something that was largely overlooked just a few years ago.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: 6 Ways To Support Your Glymphatic System and Brain Health